Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Documented progression from most recent line of therapy
• 1-3 prior lines of therapy
• Measurable disease
• Life expectancy ≥3 months
• Prior treatment with Lenalidomide permitted if:
• Best response achieved was ≥Partial Response (PR)
• Patient was not refractory
• Patient did not discontinue due to a Grade ≥3 related adverse event
• Subject did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression

Exclusion Criteria

• Subjects with non-secretory or oligo-secretory or serum free light-chain only myeloma
• Active plasma cell leukemia
• Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C